Login Register Cart 0
Generic placeholder image

Current Diabetes Reviews

Editor-in-Chief

ISSN (Print): 1573-3998
ISSN (Online): 1875-6417

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Inflammatory Biomarkers as Predictors of Infected Diabetic Foot Ulcer

Author(s): Mariya Dmitriyeva*, Zhanar Kozhakhmetova, Saltanat Urazova, Saken Kozhakhmetov, Dulat Turebayev and Medet Toleubayev

Volume 18, Issue 6, 2022

Published on: 11 January, 2022

Article ID: e280921196867 Pages: 8

DOI: 10.2174/1573399817666210928144706

Price: $65

Abstract

Diabetic foot ulcer infection is a crucial complication associated with lower-limb amputation and postoperative mortality in individuals with diabetes mellitus. Deciding if a diabetic foot ulcer is infected in a community setting is challenging without validated point-of-care tests. Early detection of infected diabetic foot ulcers can reduce the frequency of hospitalizations, the occurrence of disability, and chances of mortality. Inflammatory biomarkers are predictors of infected diabetic foot ulcers and lower-limb amputation. Procalcitonin, CRP, pentraxin-3, interleukin-6, and calprotectin may help distinguish uninfected from mildly infected diabetic foot ulcers and diagnose soft tissue infections, bone lesions, and sepsis in diabetic patients. Moreover, these biomarkers may be predictors of lower-limb amputation and postoperative mortality. The current management of infected diabetic foot ulcers is disappointing and unsatisfactory, both in preventing its development and halting and modifying its progression. The use of new (molecular) techniques for the identification of the IDFU has not yet to be proven superior to classic cultural techniques for the management of such patients. For clinicians, if the risk stratification of DFU can be obtained earlier in diabetic patients, the hospitalization, disability, and mortality rate will be reduced. For the practical application of these biomarkers, it is important to correlate these quantitative parameters with clinical symptoms. Based on clinical observations and inflammatory biomarker evaluation, it can be used to guide clinical treatment methods. This review details clinical information published during the past several decades and discusses inflammatory biomarkers that may determine the risk and level of infection of diabetic foot ulcers.

Keywords: Diabetes mellitus, diabetic foot ulcer, infection, inflammatory biomarker, procalcitonin, c-reactive protein, pentraxin, calprotectin, interleukin-6.

[1]
Lavery LA, Lavery DC, Hunt NA, La Fontaine J, Ndip A, Boulton AJ. Amputations and foot-related hospitalisations disproportionately affect dialysis patients. Int Wound J 2015; 12(5): 523-6.
[http://dx.doi.org/10.1111/iwj.12146] [PMID: 24103293]
[2]
Shin JY, Roh SG, Sharaf B, Lee NH. Risk of major limb amputation in diabetic foot ulcer and accompanying disease: A meta-analysis. J Plast Reconstr Aesthet Surg 2017; 70(12): 1681-8.
[http://dx.doi.org/10.1016/j.bjps.2017.07.015] [PMID: 28865989]
[3]
Prompers L, Huijberts M, Apelqvist J, et al. High prevalence of ischaemia, infection and serious comorbidity in patients with diabetic foot disease in Europe. Baseline results from the Eurodiale study. Diabetologia 2007; 50(1): 18-25.
[http://dx.doi.org/10.1007/s00125-006-0491-1] [PMID: 17093942]
[4]
Pichu S, Patel B M, Apparsundaram S, Goyal R K. Role of biomarkers in predicting diabetes complications with special reference to diabetic foot ulcers. Biomark Med 2017; 11: 377-88.
[http://dx.doi.org/10.2217/bmm-2016-0205]
[5]
American Diabetes Association, 2. Classification and diagnosis of diabetes: Standards of medical care in diabetes-2020. Diabetes Care 2020; 43(1)(Suppl. 1): S14-31.
[http://dx.doi.org/10.2337/dc20-S002] [PMID: 31862745]
[6]
Wang J, Zhou Y, Li Y, Xu Y, Liu G, Lu Z. Extensive serum biomarker analysis before and after treatment in healing of diabetic foot ulcers using a cytokine antibody array. Cytokine 2020; 133: 155173.
[http://dx.doi.org/10.1016/j.cyto.2020.155173] [PMID: 32585582]
[7]
Lim JZ, Ng NS, Thomas C, Thomas C. Prevention and treatment of diabetic foot ulcers. J R Soc Med 2017; 110(3): 104-9.
[http://dx.doi.org/10.1177/0141076816688346] [PMID: 28116957]
[8]
Morey M, O’Gaora P, Pandit A, Hélary C. Hyperglycemia acts in synergy with hypoxia to maintain the pro-inflammatory phenotype of macrophages. PLoS One 2019; 14(8): e0220577.
[http://dx.doi.org/10.1371/journal.pone.0220577] [PMID: 31415598]
[9]
Dörr S, Schlecht M, Chatzitomaris A, et al. Predictive Effect of Inflammatory Response and Foot Ulcer Localization on Outcome in Younger and Older Individuals with Infected Diabetic Foot Syndrome. Exp Clin Endocrinol Diabetes 2020. [Online ahead of print].
[http://dx.doi.org/10.1055/a-1149-8989] [PMID: 32583377]
[10]
Ndosi M, Wright-Hughes A, Brown S, et al. Prognosis of the infected diabetic foot ulcer: A 12-month prospective observational study. Diabet Med 2018; 35(1): 78-88.
[http://dx.doi.org/10.1111/dme.13537] [PMID: 29083500]
[11]
Ingram JR, Cawley S, Coulman E, et al. Levels of wound calprotectin and other inflammatory biomarkers aid in deciding which patients with a diabetic foot ulcer need antibiotic therapy (INDUCE study). Diabet Med 2018; 35(2): 255-61.
[http://dx.doi.org/10.1111/dme.13431] [PMID: 28734103]
[12]
Jeandrot A, Richard JL, Combescure C, et al. Serum procalcitonin and C-reactive protein concentrations to distinguish mildly infected from non-infected diabetic foot ulcers: A pilot study. Diabetologia 2008; 51(2): 347-52.
[http://dx.doi.org/10.1007/s00125-007-0840-8] [PMID: 17934713]
[13]
Pfäfflin A, Schleicher E. Inflammation markers in point-of-care testing (POCT). Anal Bioanal Chem 2009; 393(5): 1473-80.
[http://dx.doi.org/10.1007/s00216-008-2561-3] [PMID: 19104782]
[14]
Seamark DA, Backhouse SN, Powell R. Field-testing and validation in a primary care setting of a point-of-care test for C-reactive protein. Ann Clin Biochem 2003; 40(Pt 2): 178-80.
[http://dx.doi.org/10.1258/000456303763046139] [PMID: 12662408]
[15]
Chen CC, Huang JL, Chang CJ, Kong MS. Fecal calprotectin as a correlative marker in clinical severity of infectious diarrhea and usefulness in evaluating bacterial or viral pathogens in children. J Pediatr Gastroenterol Nutr 2012; 55(5): 541-7.
[http://dx.doi.org/10.1097/MPG.0b013e318262a718] [PMID: 22699836]
[16]
Van Asten SA, Nichols A, La Fontaine J, Bhavan K, Peters EJ, Lavery LA. The value of inflammatory markers to diagnose and monitor diabetic foot osteomyelitis. Int Wound J 2017; 14(1): 40-5.
[http://dx.doi.org/10.1111/iwj.12545] [PMID: 26634954]
[17]
Velissaris D, Pantzaris ND, Platanaki C, Antonopoulou N, Gogos C. Procalcitonin as a diagnostic and prognostic marker in diabetic foot infection. A current literature review. Rom J Intern Med 2018; 56(1): 3-8.
[http://dx.doi.org/10.1515/rjim-2017-0039] [PMID: 29028632]
[18]
Schneider HG, Lam QT. Procalcitonin for the clinical laboratory: A review. Pathology 2007; 39(4): 383-90.
[http://dx.doi.org/10.1080/00313020701444564] [PMID: 17676478]
[19]
Schuetz P, Christ-Crain M, Müller B. Procalcitonin and other biomarkers to improve assessment and antibiotic stewardship in infections-hope for hype? Swiss Med Wkly 2009; 139(23-24): 318-26.
[PMID: 19529989]
[20]
Hausfater P. Le dosage de la procalcitonine en pratique clinique chez l’adulte. La Rev. Med Interne 2007; 28: 296-305.
[http://dx.doi.org/10.1016/j.revmed.2006.11.003]
[21]
Al-Shammaree SAW, Abu-ALkaseem BA, Salman IN. Procalcitonin levels and other biochemical parameters in patients with or without diabetic foot complications. J Res Med Sci 2017; 22: 95.
[http://dx.doi.org/10.4103/jrms.JRMS_906_16] [PMID: 28900451]
[22]
Uzun G, Solmazgul E, Curuksulu H, et al. Procalcitonin as a diagnostic aid in diabetic foot infections. Tohoku J Exp Med 2007; 213(4): 305-12.
[http://dx.doi.org/10.1620/tjem.213.305] [PMID: 18075234]
[23]
Jafari NJ, Firouzabadi MS, Izadi M, Saburi A. Can procalcitonin be an accurate diagnostic marker for the classification of diabetic foot ulcers? Int J Endocrinol Metab 2014; 12(1): 13376.
[24]
Umapathy D, Dornadula S, Rajagopalan A, et al. Potential of circulatory procalcitonin as a biomarker reflecting inflammation among South Indian diabetic foot ulcers. J Vasc Surg 2018; 67(4): 1283-1291.e2.
[http://dx.doi.org/10.1016/j.jvs.2017.02.060] [PMID: 28736121]
[25]
Massara M, De Caridi G, Serra R, et al. The role of procalcitonin as a marker of diabetic foot ulcer infection. Int Wound J 2017; 14(1): 31-4.
[http://dx.doi.org/10.1111/iwj.12536] [PMID: 26511007]
[26]
Park JH, Suh DH, Kim HJ, Lee YI, Kwak IH, Choi GW. Role of procalcitonin in infected diabetic foot ulcer. Diabetes Res Clin Pract 2017; 128: 51-7.
[http://dx.doi.org/10.1016/j.diabres.2017.04.008] [PMID: 28448892]
[27]
Li S, Rong H, Guo Q, Chen Y, Zhang G, Yang J. Serum procalcitonin levels distinguish Gram-negative bacterial sepsis from Gram-positive bacterial and fungal sepsis. J Res Med Sci 2016; 21: 39.
[http://dx.doi.org/10.4103/1735-1995.183996] [PMID: 27904585]
[28]
Korkmaz P, Koçak H, Onbaşı K, et al. The role of serum procalcitonin, interleukin-6, and fibrinogen levels in differential diagnosis of diabetic foot ulcer infection. J Diabetes Res 2018; 2018: 7104352.
[http://dx.doi.org/10.1155/2018/7104352] [PMID: 29675434]
[29]
Mutluoglu M, Uzun G, Ipcioglu OM, Sildiroglu O. Can procalcitonin predict bone infection in people with diabetes with infected foot ulcers? A pilot study. Diabet Res And Clin Pract 2001; 94: 53-6.
[30]
McFadyen JD, Kiefer J, Braig D, et al. Dissociation of C-reactive protein localizes and amplifies inflammation: Evidence for a direct biological role of c-reactive protein and its conformational changes. Front Immunol 2018; 9: 1351.
[http://dx.doi.org/10.3389/fimmu.2018.01351] [PMID: 29946323]
[31]
Weigelt C, Rose B, Poschen U, et al. Immune mediators in patients with acute diabetic foot syndrome. Diabetes Care 2009; 32(8): 1491-6.
[http://dx.doi.org/10.2337/dc08-2318] [PMID: 19509015]
[32]
Metineren H, Dülgeroğlu TC. Comparison of the neutrophil/lymphocyte ratio and c-reactive protein levels in patients with amputation for diabetic foot ulcers. Int J Low Extrem Wounds 2017; 16(1): 23-8.
[http://dx.doi.org/10.1177/1534734617696729] [PMID: 28682678]
[33]
Pickwell K, Siersma V, Kars M, et al. Predictors of lower-extremity amputation in patients with an infected diabetic foot ulcer. Diabetes Care 2015; 38(5): 852-7.
[http://dx.doi.org/10.2337/dc14-1598] [PMID: 25665817]
[34]
Tecilazich F, Dinh T, Pradhan-Nabzdyk L, et al. Role of endothelial progenitor cells and inflammatory cytokines in healing of diabetic foot ulcers. PLoS One 2013; 8(12): e83314.
[http://dx.doi.org/10.1371/journal.pone.0083314] [PMID: 24358275]
[35]
van Asten SAV, Jupiter DC, Mithani M, La Fontaine J, Davis KE, Lavery LA. Erythrocyte sedimentation rate and C-reactive protein to monitor treatment outcomes in diabetic foot osteomyelitis. Int Wound J 2017; 14(1): 142-8.
[http://dx.doi.org/10.1111/iwj.12574] [PMID: 26953894]
[36]
Fleischer AE, Didyk AA, Woods JB, Burns SE, Wrobel JS, Armstrong DG. Combined clinical and laboratory testing improves diagnostic accuracy for osteomyelitis in the diabetic foot. J Foot Ankle Surg 2009; 48(1): 39-46.
[http://dx.doi.org/10.1053/j.jfas.2008.09.003] [PMID: 19110158]
[37]
Pham TT, Wetzel O, Gariani K, Kressmann B. Routine measurement of the serum c-reactive protein level helpful during antibiotic therapy for diabetic foot infection? Diabetes Obes Metab 2021; 23(2): 637-41.
[http://dx.doi.org/10.1111/dom.14222] [PMID: 33026129]
[38]
Senneville É, Lipsky BA, Abbas ZG, et al. Diagnosis of infection in the foot in diabetes: A systematic review. Diabetes Metab Res Rev 2020; 36(Suppl. 1): e3281.
[http://dx.doi.org/10.1002/dmrr.3281] [PMID: 32176440]
[39]
Lee SJ, Jung YC, Jeon DO, et al. High serum C-reactive protein level predicts mortality in patients with stage 3 chronic kidney disease or higher and diabetic foot infections. Kidney Res Clin Pract 2013; 32(4): 171-6.
[http://dx.doi.org/10.1016/j.krcp.2013.10.001] [PMID: 26877937]
[40]
Uçkay I, Garzoni C, Ferry T, et al. Postoperative serum pro-calcitonin and C-reactive protein levels in patients with orthopedic infections. Swiss Med Wkly 2010; 140: w13124.
[http://dx.doi.org/10.4414/smw.2010.13124] [PMID: 21104474]
[41]
Ong E, Farran S, Salloum M, et al. Does everything that’s counted count? Value of inflammatory markers for following therapy and predicting outcome in diabetic foot infection. Int J Low Extrem Wounds 2017; 16(2): 104-7.
[http://dx.doi.org/10.1177/1534734617700539] [PMID: 28682724]
[42]
Uçkay I, Gariani K, Pataky Z, Lipsky BA. Diabetic foot infections: state-of-the-art. Diabetes Obes Metab 2014; 16(4): 305-16.
[http://dx.doi.org/10.1111/dom.12190] [PMID: 23911085]
[43]
Gariani K, Lebowitz D, von Dach E, Kressmann B, Lipsky BA, Uçkay I. Remission in diabetic foot infections: Duration of antibiotic therapy and other possible associated factors. Diabetes Obes Metab 2019; 21(2): 244-51.
[http://dx.doi.org/10.1111/dom.13507] [PMID: 30129109]
[44]
Uzun S, Ozari M, Gursu M, et al. Changes in the inflammatory markers with advancing stages of diabetic nephropathy and the role of pentraxin-3. Ren Fail 2016; 38(8): 1193-8.
[http://dx.doi.org/10.1080/0886022X.2016.1209031] [PMID: 27436699]
[45]
Shindo A, Tanemura H, Yata K, et al. Inflammatory biomarkers in atherosclerosis: Pentraxin 3 can become a novel marker of plaque vulnerability. PLoS One 2014; 9(6): e100045.
[http://dx.doi.org/10.1371/journal.pone.0100045] [PMID: 24936646]
[46]
Zhou Y, Ni Z, Zhang J, et al. Plasma pentraxin 3 may be a better marker of peripheral artery disease in hemodialysis patients than C-reactive protein. Vasc Med 2013; 18(2): 85-91.
[http://dx.doi.org/10.1177/1358863X13483864] [PMID: 23609129]
[47]
Presta M, Camozzi M, Salvatori G, Rusnati M. Role of the soluble pattern recognition receptor PTX3 in vascular biology. J Cell Mol Med 2007; 11(4): 723-38.
[http://dx.doi.org/10.1111/j.1582-4934.2007.00061.x] [PMID: 17760835]
[48]
Abu SN, Witasp A, Wan MW, et al. Evaluation of the association of plasma pentraxin 3 levels with type 2 diabetes and diabetic nephropathy in a Malay population. J Diabetes Res 2013; 298019.
[http://dx.doi.org/10.1155/2013/298019] [PMID: 24350299]
[49]
Ozer Balin S, Sagmak Tartar A, Uğur K, et al. Pentraxin-3: A new parameter in predicting the severity of diabetic foot infection? Int Wound J 2019; 16(3): 659-64.
[http://dx.doi.org/10.1111/iwj.13075] [PMID: 30767386]
[50]
Reiner MM, Khoury WE, Canales MB, et al. Procalcitonin as a biomarker for predicting amputation level in lower extremity infections. J Foot Ankle Surg 2017; 56(3): 484-91.
[http://dx.doi.org/10.1053/j.jfas.2017.01.014] [PMID: 28341493]
[51]
Karakas A, Arslan E, Cakmak T, Aydin I, Akgul EO, Demirbas S. Predictive value of soluble CD14, Interleukin-6 and Procalcitonin for lower extremity amputation in people with diabetes with foot ulcers: a pilot study. Pak J Med Sci 2014; 30(3): 578-82.
[PMID: 24948983]
[52]
Altay FA, Sencan İ, Şentürk GÇ, et al. Does treatment affect the levels of serum interleukin-6, interleukin-8 and procalcitonin in diabetic foot infection? A pilot study. J Diabetes Complications 2012; 26(3): 214-8.
[http://dx.doi.org/10.1016/j.jdiacomp.2012.03.018] [PMID: 22521320]
[53]
Kolumam G, Wu X, Lee WP, et al. IL-22R ligands IL-20, IL-22, and IL24 promote wound healing in diabetic db/db mice. PLoS One 2017; 12(1): e0170639.
[http://dx.doi.org/10.1371/journal.pone.0170639] [PMID: 28125663]
[54]
Karkada G, Maiya GA, Houreld NN, et al. Effect of photobiomodulation therapy on inflammatory cytokines in healing dynamics of diabetic wounds: A systematic review of preclinical studies. Arch Physiol Biochem 2020; 1-8.
[http://dx.doi.org/10.1080/13813455.2020.1861025] [PMID: 33370535]
[55]
Sekimoto R, Kishida K, Nakatsuji H, Nakagawa T, Funahashi T, Shimomura I. High circulating levels of S100A8/A9 complex (calprotectin) in male Japanese with abdominal adiposity and dysregulated expression of S100A8 and S100A9 in adipose tissues of obese mice. Biochem Biophys Res Commun 2012; 419(4): 782-9.
[http://dx.doi.org/10.1016/j.bbrc.2012.02.102] [PMID: 22390934]
[56]
Peng WH, Jian WX, Li HL, et al. Increased serum myeloid-related protein 8/14 level is associated with atherosclerosis in type 2 diabetic patients. Cardiovasc Diabetol 2011; 10: 41.
[http://dx.doi.org/10.1186/1475-2840-10-41] [PMID: 21592353]
[57]
Mortensen OH, Nielsen AR, Erikstrup C, et al. Calprotectin-a novel marker of obesity. PLoS One 2009; 4(10): e7419.
[http://dx.doi.org/10.1371/journal.pone.0007419] [PMID: 19823685]
[58]
Catalán V, Gómez-Ambrosi J, Rodríguez A, et al. Increased levels of calprotectin in obesity are related to macrophage content: impact on inflammation and effect of weight loss. Mol Med 2011; 17(11-12): 1157-67.
[http://dx.doi.org/10.2119/molmed.2011.00144] [PMID: 21738950]
[59]
Ortega FJ, Sabater M, Moreno-Navarrete JM, et al. Serum and urinary concentrations of calprotectin as markers of insulin resistance and type 2 diabetes. Eur J Endocrinol 2012; 167(4): 569-78.
[http://dx.doi.org/10.1530/EJE-12-0374] [PMID: 22822112]
[60]
Schmaderer C, Kemmner S, Burkhardt K, Heemann U, Baumann M. Serum myeloid-related protein 8/14 complex is associated with microalbuminuria in patients with type 2 diabetes. Ther Adv Cardiovasc Dis 2014; 8(3): 80-8.
[http://dx.doi.org/10.1177/1753944714528270] [PMID: 24667921]
[61]
Tabur S, Korkmaz H, Ozkaya M, Aksoy SN, Akarsu E. Is calprotectin a novel biomarker of neuroinflammation in diabetic periferal neuropathy? Diabetol Metab Syndr 2015; 7(36): 36.
[http://dx.doi.org/10.1186/s13098-015-0030-7] [PMID: 25995771]
[62]
Victoria van Asten SA, Geradus Peters EJ, Xi Y, Lavery LA, Lavery LA. The role of biomarkers to diagnose diabetic foot osteomyelitis. a meta-analysis. Curr Diabetes Rev 2016; 12(4): 396-402.
[http://dx.doi.org/10.2174/1573399811666150713104401] [PMID: 26166314]
[63]
Lavery LA, Ryan EC, Ahn J, et al. The infected diabetic foot: re-evaluating the infectious diseases society of america diabetic foot infection classification. Clin Infect Dis 2020; 70(8): 1573-9.
[http://dx.doi.org/10.1093/cid/ciz489] [PMID: 31179491]
[64]
Lipsky BA. A report from the international consensus on diagnosing and treating the infected diabetic foot. Diabetes Metab Res Rev 2004; 20(1): S68-77.
[http://dx.doi.org/10.1002/dmrr.453] [PMID: 15150818]
[65]
Armstrong DG, Fiorito JL, Leykum BJ, Mills JL. Clinical efficacy of the pan metatarsal head resection as a curative procedure in patients with diabetes mellitus and neuropathic forefoot wounds. Foot Ankle Spec 2012; 5(4): 235-40.
[http://dx.doi.org/10.1177/1938640012449038] [PMID: 22715496]
[66]
Ramirez-Acuña JM, Cardenas-Cadena SA, Marquez-Salas PA, et al. Diabetic foot ulcers: current advances in antimicrobial therapies and emerging treatments. Antibiotics (Basel) 2019; 8(4): 193.
[http://dx.doi.org/10.3390/antibiotics8040193] [PMID: 31652990]

Rights & Permissions Print Cite
Article Metrics
21
1
© 2024 Bentham Science Publishers | Privacy Policy